27616047|t|Plasmodium falciparum Choline Kinase Inhibition Leads to a Major Decrease in Phosphatidylethanolamine Causing Parasite Death
27616047|a|Malaria is a life-threatening disease caused by different species of the protozoan parasite Plasmodium, with P. falciparum being the deadliest. Increasing parasitic resistance to existing antimalarials makes the necessity of novel avenues to treat this disease an urgent priority. The enzymes responsible for the synthesis of phosphatidylcholine and phosphatidylethanolamine are attractive drug targets to treat malaria as their selective inhibition leads to an arrest of the parasite's growth and cures malaria in a mouse model. We present here a detailed study that reveals a mode of action for two P. falciparum choline kinase inhibitors both in vitro and in vivo. The compounds present distinct binding modes to the choline / ethanolamine - binding site of P. falciparum choline kinase, reflecting different types of inhibition. Strikingly, these compounds primarily inhibit the ethanolamine kinase activity of the P. falciparum choline kinase, leading to a severe decrease in the phosphatidylethanolamine levels within P. falciparum, which explains the resulting growth phenotype and the parasites death. These studies provide an understanding of the mode of action, and act as a springboard for continued antimalarial development efforts selectively targeting P. falciparum choline kinase.
27616047	0	21	Plasmodium falciparum	T204	UMLS:C0032150
27616047	22	36	Choline Kinase	T103	UMLS:C0008415
27616047	77	101	Phosphatidylethanolamine	T103	UMLS:C1450468
27616047	110	118	Parasite	T204	UMLS:C0030498
27616047	119	124	Death	T038	UMLS:C0011065
27616047	125	132	Malaria	T038	UMLS:C0024530
27616047	138	154	life-threatening	T033	UMLS:C2826244
27616047	155	162	disease	T038	UMLS:C0012634
27616047	183	190	species	T170	UMLS:C1705920
27616047	198	216	protozoan parasite	T204	UMLS:C0585171
27616047	217	227	Plasmodium	T204	UMLS:C0032148
27616047	234	247	P. falciparum	T204	UMLS:C0032150
27616047	313	326	antimalarials	T103	UMLS:C0003374
27616047	367	372	treat	T058	UMLS:C0087111
27616047	378	385	disease	T038	UMLS:C0012634
27616047	410	417	enzymes	T103	UMLS:C0014442
27616047	451	470	phosphatidylcholine	T103	UMLS:C1959616
27616047	475	499	phosphatidylethanolamine	T103	UMLS:C1450468
27616047	531	536	treat	T058	UMLS:C0087111
27616047	537	544	malaria	T038	UMLS:C0024530
27616047	601	611	parasite's	T204	UMLS:C0030498
27616047	612	618	growth	T038	UMLS:C0018270
27616047	629	636	malaria	T038	UMLS:C0024530
27616047	642	653	mouse model	T038	UMLS:C2986594
27616047	682	687	study	T062	UMLS:C2603343
27616047	726	739	P. falciparum	T204	UMLS:C0032150
27616047	740	754	choline kinase	T103	UMLS:C0008415
27616047	755	765	inhibitors	T103	UMLS:C0243077
27616047	784	791	in vivo	T082	UMLS:C1515655
27616047	824	831	binding	T038	UMLS:C1167622
27616047	845	852	choline	T103	UMLS:C0008405
27616047	855	867	ethanolamine	T103	UMLS:C0059696
27616047	870	882	binding site	T103	UMLS:C0005456
27616047	886	899	P. falciparum	T204	UMLS:C0032150
27616047	900	914	choline kinase	T103	UMLS:C0008415
27616047	1008	1036	ethanolamine kinase activity	T038	UMLS:C1150468
27616047	1044	1057	P. falciparum	T204	UMLS:C0032150
27616047	1058	1072	choline kinase	T103	UMLS:C0008415
27616047	1110	1134	phosphatidylethanolamine	T103	UMLS:C1450468
27616047	1149	1162	P. falciparum	T204	UMLS:C0032150
27616047	1218	1227	parasites	T204	UMLS:C0030498
27616047	1228	1233	death	T038	UMLS:C0011065
27616047	1336	1360	antimalarial development	T038	UMLS:C0243107
27616047	1391	1404	P. falciparum	T204	UMLS:C0032150
27616047	1405	1419	choline kinase	T103	UMLS:C0008415